Taxed at 94%, Now on the NYSE: Glass House Brands ($GLAS)

RoboSystems Initiating Coverage - Cannabis · July 16, 2026 · NYSE: GLAS (uplisted June 30, 2026; formerly OTCQX: GLASF) · CIK 0001848731 · Primary filing: FY2025 Form 40-F (filed March 24, 2026) plus Q1 2026 results

The Hook

In fiscal 2024, Glass House Brands earned $11.2 million in pretax income - and was charged $10.5 million of it in income tax. That is a 94% effective tax rate, against the 21% a normal American company pays, because Section 280E of the tax code bars cannabis operators from deducting ordinary business expenses. In fiscal 2025 it got stranger: the company reported a $17.0 million pretax loss and still booked an $11.9 million tax expense. Over the last four fiscal years, Glass House has accrued roughly $38 million in current income taxes against a cumulative pretax loss of about $131 million. Those numbers come straight from the company's SEC filings, queried live from the RoboSystems SEC graph.

Yet on June 30, 2026, this company became only the second US plant-touching cannabis operator in history to trade on the New York Stock Exchange - and the reason nobody covering the uplisting headline talks about is the one that matters: Glass House grows cannabis for $111 a pound at scale, in a country where operators east of the Mississippi are widely cited at $900 or more, and where Europe pays multiples of California prices. That 8-to-1 cost gap has been locked behind a federal wall for the company's entire existence. In April 2026, the wall cracked.

Company Snapshot

Glass House is a vertically integrated, California-only operator built around the largest single cannabis farm in the United States: a 160-acre former tomato-and-cucumber greenhouse complex in Camarillo with 5.5 million square feet of cultivation footprint across six greenhouses, powered by free sun, 12.8 megawatts of on-site cogeneration at roughly nine cents a kilowatt-hour, and its own wells. Management's full-capacity estimate is 1.6 million pounds a year once all retrofits are complete. Revenue comes from three segments - wholesale biomass (59% of Q1 2026 revenue), ten retail dispensaries (The Farmacy, NHC, The Pottery), and CPG brands (Glass House Farms, PLUS, Allswell, Mama Sue Wellness). FY2025 revenue was $182.0 million. It files a 40-F on a calendar fiscal year; all figures below are from the RoboSystems SEC graph, the Q1 2026 earnings release (May 13, 2026), or attributed sources.

The Financial Story

The revenue arc tells you what kind of company this is. Sales ran $84.9 million in FY2022, $160.8 million in FY2023, $200.9 million in FY2024, then dipped to $182.0 million in FY2025 - a 9% decline in the same year the company grew production 10% to 666,433 pounds and sold 13% more pounds than the year before. The entire decline is price: wholesale biomass average selling price fell 28%, from $245 a pound in FY2024 to $177 in FY2025. Glass House expanded straight through the industry bust - and California wholesale deflation ate the top line anyway. That is what "training at altitude," as CEO Kyle Kazan calls the California market, actually looks like in the numbers.

Then came the quarter that tested the whole cost-leadership thesis. In Q1 2026, cost per pound spiked to $175 - above the $171 average selling price. Gross margin collapsed to 25% from 45% a year earlier, adjusted EBITDA swung to negative $4.2 million, and operating cash flow was negative $11.8 million. The cause traces to July 10, 2025, when federal immigration agents raided the Camarillo and Carpinteria farms - roughly 360 arrests and a worker death, per contemporaneous reporting - forcing Glass House to rebuild its trained cultivation workforce with third-party contractors even as it accelerated two greenhouse build-outs. Management cut full-year cost guidance from about $100 to about $111 a pound but held the rest: roughly 1,000,000 pounds of production in 2026 (a company record), revenue of $235-245 million, mid-40s gross margin, adjusted EBITDA in the high $30 millions, and a return to the $95-a-pound quarterly cost target in the second half. Q2 guidance calls for $55-60 million of revenue on 240,000 pounds. Co-founder Graham Farrar's case on the call was blunt: the team hit $91 a pound in Q2 2025, and "there is nothing structurally that takes that away from us."

The tax line is where Glass House stops looking like a farm and starts looking like a policy case study. Because 280E only allows cost of goods sold as a deduction, the company's FY2024 effective tax rate was 94%; a normal rate of about 25% (the 21% federal rate plus state tax) would have cost about $2.8 million instead of $10.5 million - a roughly $7.7 million penalty in the company's only profitable year. Rather than keep writing checks it believes it won't ultimately owe, Glass House has been accruing the dispute: its unrecognized tax benefit reserve grew from $2.8 million at the end of FY2022 to $5.4 million (FY2023), $20.9 million (FY2024), and $31.7 million at year-end FY2025 - and, per CFO Mark Vendetti on the May 13 call, almost $35 million at the end of Q1 2026, with the Q1 tax provision of $3.1 million "comprised almost entirely of 280E tax impact."

The balance sheet is unusual for cannabis - in both directions. Debt is modest: $67.9 million of notes, anchored by a $50 million secured facility at 8.58% due February 2030, with only $14.7 million of convertibles due April 2027 - no 2026 maturity wall. Goodwill is zero (the company impaired $43.8 million of it in 2022-2023, and intangibles are down to $11.6 million), and there is $228.8 million of owned property and equipment against $318.6 million of total assets - this is a real-asset story, not a roll-up. The catch is the preferred stack: $92.5 million of preferred equity paying 12% (Series E) and 15% stepping to 20% in 2028 (Series D) - nearly $11.6 million a year in dividends on today's run rate. Add cash of $27.9 million, a $22.3 million at-the-market raise completed in Q1 at about $8.15 a share, and a fresh $50 million ATM filed July 15, and the picture is clear: growth is being funded with equity and expensive preferreds, and the company was operating-cash-flow positive in FY2023-FY2025 ($23.2 million, $28.4 million, $11.4 million) before the Q1 2026 step back.

Catalyst Scenarios - How the Math Changes

280E relief - with an all-medical twist. The April 28, 2026 Schedule III order covers state-licensed medical cannabis only, and here Glass House did something structurally different from every multi-state peer: it converted all of its cultivation and processing licenses to medical and registered with the Drug Enforcement Administration (a Form 225 bulk-manufacturer registration, submitted per the Q1 call). If that interpretation holds, essentially the entire remaining business - not a medical slice - qualifies for 280E relief, and the announced IRS transition rule applies it to the full 2026 tax year for calendar filers. The math: the 280E drag has been running about $12 million a year ($11.9 million of tax expense in FY2025 on a pretax loss; $3.1 million accrued in Q1 2026 alone). Against guided high-$30-millions adjusted EBITDA, removing that line is roughly a 30% uplift to underlying cash earnings power. Two honest caveats: relief is prospective - the ~$35 million reserve for back years stays a liability, not a refund (the IRS is actively clawing back "rescheduling gambit" refunds sector-wide, with aggregate MSO exposure around $1.6 billion per MJBizDaily) - and Glass House was still accruing 280E in Q1 while its advisers work out, in the CFO's words, "if and how much of our uncertain tax liability can be eliminated."

Uplisting - already fired. Glass House deconsolidated its dual-use business (Glass House Retail, LLC) on June 17 - a third-party investor holds the voting units, while Glass House keeps non-voting, non-participating units that convert back only if the NYSE ever permits consolidating non-medical cannabis - and began trading as GLAS on June 30, the second plant-touching operator on a major US exchange after Trulieve's June 10 debut. The re-rating case is liquidity, index eligibility, and institutional access (the MSOS ETF has begun converting Trulieve swaps into direct shares). Housekeeping helped too: the entire 30.7-million SPAC-warrant overhang was redeemed in May.

Interstate commerce and export - the thesis-defining option. Management's reading is that Schedule III plus DEA registration permits medical interstate transfer and export between properly registered parties; an export permit (Form 161) awaits approval of the base registration, which the final order requires the agency to process within six months, and the company says it is negotiating out-of-state sales mechanics with California regulators now. Nobody has done this yet - that is the risk and the prize. The price ladder explains why it dominates the story: Glass House sells biomass at $171-185 a pound in California; Farrar noted an eighth retails around $35 in New Jersey versus $7.50 at his own stores; short-seller-turned-bull Marc Cohodes put East-of-Mississippi production costs at $900-1,000 a pound on the Q1 call, and management called those numbers "certainly within the realm." Even at a heavily discounted $400-a-pound realized price on exported or interstate pounds, gross profit per pound would roughly quadruple versus California economics. On a million guided pounds - let alone 1.6 million at full capacity - every $100 a pound of incremental realized price is roughly $100 million of incremental gross profit. None of this is in 2026 guidance.

Hemp and consolidation - smaller, but live now. On July 7 the company completed its first international sale of any product: smokeable CBD hemp biomass from Greenhouse 4 to Europe. GH4 can produce about 100,000 pounds of hemp annually today (about 300,000 with a full retrofit), management says pricing is favorable to California cannabis, and all of it is incremental to guidance. Separately, the announced 50/50 California retail joint venture with Vireo Growth (Glass House contributes its ten stores; Vireo contributes Eaze dispensaries and delivery) would consolidate distressed California retail with a built-in supply agreement - and the federal intoxicating-hemp ban effective November 2026 should, in a channel state like California (AB 8 routes intoxicating hemp into licensed dispensaries), push displaced demand toward exactly these stores.

Valuation - What It's Worth If the Options Are Real

Start with where it trades, because Glass House inverts the sector's usual setup. At about $10.50 (intraday July 16), market cap is roughly $890 million on 85.1 million shares; adding $67.9 million of debt and $92.5 million of preferred, less $27.9 million of cash, enterprise value is just over $1.0 billion. Against FY2026 guidance that is about 4.3 times forward revenue and roughly 27 times forward adjusted EBITDA - while Tier-1 MSOs trade at 0.9-3.0 times revenue and 3-14 times EBITDA (SSC Advisors comps, May 29, 2026). Every other cannabis name we cover is a story about a discount; Glass House is the one name where the market has already paid a premium for the catalysts. The question is not "what if it re-rates" - it is whether the options being priced are real.

Band the scenarios with stated assumptions. A base case - California-only, 280E persists, guidance hit - supports perhaps $185-370 million of enterprise value (high-$30-millions EBITDA at the 5-10 times of quality peers): meaningfully below today's price, which tells you the market ascribes $600-800 million to optionality. A 280E-relief case (all-medical structure holds, prospective relief from 2026) adds about $12 million a year of after-tax earnings power - call it $250-500 million of value at the same multiples, still shy of today. The number that closes the gap is export/interstate: if even half of guided production ultimately clears at $400-500 a pound against a $95-111 cost base, incremental gross profit runs $150-200 million a year, and EBITDA in the $150-250 million range at 8-10 times supports a $1.2-2.5 billion enterprise - with full-capacity 1.6-million-pound scenarios well beyond that. In plain terms: today's price implies meaningful-but-partial probability on the export option. If the D.C. Circuit stays the rescheduling order, the floor is a California greenhouse business in deflation at 27 times EBITDA. These are implied values under stated assumptions - not price targets, and not advice.

Risks and Open Questions

The stack of risk here is unusually binary. The pending D.C. Circuit challenge could stay or vacate the partial Schedule III order - which would undercut the NYSE listing's legal predicate, reverse any 280E relief assumptions, and hit this stock harder than peers precisely because more hope is priced in. The interstate/export legal theory is untested: it requires DEA registration approvals on the mandated timeline, an export permit, cooperative California mechanics for product leaving the state, and receiving jurisdictions that agree - and if the door does open, every low-cost grower follows, compressing the very price gap that makes the math sing. Execution risk is live and current: cost per pound was $175 last quarter against a $95 second-half target, the workforce is still being retrained post-raid, and management already cut cost and EBITDA guidance once this year. Financing is dilutive by design - an active $50 million ATM and $92.5 million of 12-20% preferreds that consume most base-case cash generation. And the back-tax reserve near $35 million is real money the IRS shows no inclination to forgive. Watch also whether hemp economics survive the November 2026 federal hemp ban's final form - management says its smokable CBD product is compliant either way, but the rules are in flux.

The Bottom Line

Glass House today is a $182-million-revenue California farm with the lowest verified cost structure in US cannabis, a broken quarter it has to prove was transitory, and a tax line that shows what 280E does to even a well-run operator - 94 cents of every pretax dollar in its one profitable year. What changed in 2026 is that its three biggest constraints - taxes, capital access, and the state border - all cracked in the span of ten weeks: full medical conversion for 280E relief, a NYSE ticker, and a registration pathway management believes leads to interstate and export sales, with a first hemp shipment to Europe already landed. The watch list from here: the D.C. Circuit stay decision, the DEA administrative law judge's recommendation on broad rescheduling (the hearing concluded July 15), Form 225/161 approvals and California's export mechanics, cost per pound in the August Q2 print, and first hemp revenue in the second half. The bear case is a 27-times-EBITDA farm in a deflating market whose options expire in court. The bull case is the only public operator whose cost structure works at world prices, listed on the NYSE, first in line at a door that just started to open. The filing data frames both; the reader decides.

---

This analysis was built with RoboSystems - open-source tools for querying structured SEC filing data directly. Try it at robosystems.ai. New customers get 50% off your first month with code CANNABIS50.

Not investment advice. No price targets, no buy or sell recommendations. All filing figures queried from the RoboSystems SEC graph (CIK 0001848731, FY2025 40-F and prior filings) on July 16, 2026; quarterly figures from the company's Q1 2026 earnings release and call (May 13, 2026); market prices intraday July 16, 2026. Attributed third-party claims (East Coast production costs, raid reporting, sector comps) are identified in the text and were not independently verified.